ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,617.19
0.20%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Hutchison China Meditech Ltd (0J7G)

  7. Hutchison China Meditech Ltd (0J7G) News

Hutchison China Meditech (0J7G)

Hutchison China Meditech Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0J7G
DateTimeSourceHeadlineSymbolCompany
11/01/202407:00RNS Non-RegulatoryHutchmed (China) Limited Sovleplenib NDA Granted Priority Review in ChinaLSE:0J7GHutchison China Meditech Ltd
29/12/202308:30UK RegulatoryHutchmed (China) Limited Total Voting RightsLSE:0J7GHutchison China Meditech Ltd
29/12/202308:30UK RegulatoryHutchmed (China) Limited Blocklisting Six Monthly ReturnLSE:0J7GHutchison China Meditech Ltd
21/12/202310:00UK RegulatoryHutchmed (China) Limited Overseas Regulatory AnnouncementLSE:0J7GHutchison China Meditech Ltd
13/12/202307:00RNS Non-RegulatoryHutchmed (China) Limited Completed Enrollment of Phase II/III TrialLSE:0J7GHutchison China Meditech Ltd
13/12/202307:00RNS Non-RegulatoryHutchmed (China) Limited Inclusion in National Reimbursement Drug ListLSE:0J7GHutchison China Meditech Ltd
07/12/202310:04UK RegulatoryHutchmed (China) Limited Overseas Regulatory AnnouncementLSE:0J7GHutchison China Meditech Ltd
01/12/202307:00RNS Non-RegulatoryHutchmed (China) Limited Clinical Data to be Presented at CongressesLSE:0J7GHutchison China Meditech Ltd
30/11/202308:30UK RegulatoryHutchmed (China) Limited Total Voting RightsLSE:0J7GHutchison China Meditech Ltd
09/11/202307:00UK RegulatoryHutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM) (fruquintinib)LSE:0J7GHutchison China Meditech Ltd
24/10/202309:30UK RegulatoryHutchmed (China) Limited Vesting of awards under the LTIPLSE:0J7GHutchison China Meditech Ltd
16/10/202309:30RNS Non-RegulatoryHutchmed (China) Limited Clinical Data to be Presented at ESMO 2023LSE:0J7GHutchison China Meditech Ltd
29/09/202309:30RNS Non-RegulatoryHutchmed (China) Limited NDA Submission for Fruquintinib in JapanLSE:0J7GHutchison China Meditech Ltd
29/09/202309:30UK RegulatoryHutchmed (China) Limited Total Voting RightsLSE:0J7GHutchison China Meditech Ltd
14/09/202309:30UK RegulatoryHutchmed (China) Limited Director's Share DealingLSE:0J7GHutchison China Meditech Ltd
12/09/202309:30RNS Non-RegulatoryHutchmed (China) Limited Phase IIIb Savolitinib Results at WCLC 2023LSE:0J7GHutchison China Meditech Ltd
12/09/202307:00RNS Non-RegulatoryHutchmed (China) Limited Patient Enrollment Completed for Bridging StudyLSE:0J7GHutchison China Meditech Ltd
31/08/202309:30UK RegulatoryHutchmed (China) Limited Total Voting RightsLSE:0J7GHutchison China Meditech Ltd
29/08/202307:00RNS Non-RegulatoryHutchmed (China) Limited BTD in China for Savolitinib for Gastric CancerLSE:0J7GHutchison China Meditech Ltd
21/08/202307:00UK RegulatoryHutchmed (China) Limited Sovleplenib Phase 3 Study Meets Primary EndpointLSE:0J7GHutchison China Meditech Ltd
07/08/202309:30UK RegulatoryHutchmed (China) Limited Exercise of Share Options by a DirectorLSE:0J7GHutchison China Meditech Ltd
31/07/202312:00UK RegulatoryHutchmed (China) Limited Interim Results and Business UpdatesLSE:0J7GHutchison China Meditech Ltd
20/07/202307:00RNS Non-RegulatoryHutchmed (China) Limited Breakthrough Therapy Designation for FruquintinibLSE:0J7GHutchison China Meditech Ltd
13/07/202309:30UK RegulatoryHutchmed (China) Limited Changes to Board and Technical CommitteeLSE:0J7GHutchison China Meditech Ltd
10/07/202307:00RNS Non-RegulatoryHutchmed (China) Limited Phase 1 Study of HMPL-415 InitiatedLSE:0J7GHutchison China Meditech Ltd
29/06/202309:30UK RegulatoryHutchmed (China) Limited Blocklisting Six Monthly ReturnLSE:0J7GHutchison China Meditech Ltd
26/06/202309:30UK RegulatoryHutchmed (China) Limited HUTCHMED to Announce 2023 Half-Year ResultsLSE:0J7GHutchison China Meditech Ltd
16/06/202307:00UK RegulatoryHutchmed (China) Limited Phase III FRESCO-2 Results in The LancetLSE:0J7GHutchison China Meditech Ltd
15/06/202315:39UK RegulatoryHutchmed (China) Limited MAA of Fruquintinib Validated by the EMALSE:0J7GHutchison China Meditech Ltd
09/06/202310:30RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Highlights Presentations at EHA and ICMLLSE:0J7GHutchison China Meditech Ltd
 Showing the most relevant articles for your search:LSE:0J7G

Your Recent History

LSE
BIRD
Blackbird
LSE
ITV
Itv
LSE
POS
Plexus
LSE
GOLD
LSE
GKP
Gulf Keystone Petroleum
LSE
SCLP
Scancell
LSE
TERN
Tern
LSE
AAZ
Anglo Asian Mining
LSE
NG.
National Grid
LSE
KRS
Keras Resources
LSE
INSG
Insig Ai
LSE
BLOE
Block Energy
LSE
CNR
Condor Gold
LSE
SAR
Sareum
LSE
PPP
Pennpetro Energy
LSE
LLOY
Lloyds Banking
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved